



Revista de Psiquiatría y Salud Mental

www.elsevier.es/saludmental



REVIEW ARTICLE

Clinical staging in severe mental disorders: Bipolar disorder, depression and schizophrenia[☆]



Lorena de la Fuente-Tomas^a, Mónica Sánchez-Autet^b,
Leticia García-Álvarez^a, Leticia González-Blanco^c, Ángela Velasco^d,
Pilar A. Sáiz Martínez^a, María P. Garcia-Portilla^{a,*}, Julio Bobes^a

^a Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM G-05), Departamento de Psiquiatría, Universidad de Oviedo, Instituto de Neurociencias del Principado de Asturias (INEUROPA), Oviedo, Spain

^b Hospital Universitario Mutua Terrassa, Universidad de Barcelona, Terrasa, Spain

^c Servicio de Salud del Principado de Asturias (SESPA), Departamento de Psiquiatría, Universidad de Oviedo, Instituto de Neurociencias del Principado de Asturias (INEUROPA), Oviedo, Spain

^d Departamento de Psiquiatría, Universidad de Oviedo, Oviedo, Spain

Received 18 March 2018; accepted 2 August 2018

Available online 4 July 2019

KEYWORDS

Staging;
Psychiatry;
Bipolar disorder;
Depression;
Schizophrenia

Abstract Clinical staging is a diagnostic tool used in other medical specialties, which has resulted from the combination of a categorical and dimensional approach. In the last 2 decades, the usefulness of its application in the field of psychiatry has been suggested, mainly as a tool for diagnostic help, and therapeutic and prognostic orientation.

In this paper we review the clinical staging models that have been proposed to date for bipolar disorder, depression and schizophrenia. A literature search was performed in PubMed and Medline databases. A total of 15 studies were selected according to inclusion and exclusion criteria.

Models were grouped according to the type of disorder for which staging was proposed (bipolar disorder: 4, depression: 5, schizophrenia: 6), and their characteristics were described.

As a conclusion, we identify the need to empirically validate these models to demonstrate that staging is a useful tool for clinical practice.

© 2018 SEP y SEPB. Published by Elsevier España, S.L.U. All rights reserved.

[☆] Please cite this article as: de la Fuente-Tomas L, Sánchez-Autet M, García-Álvarez L, González-Blanco L, Velasco Á, Sáiz Martínez PA, et al. Estadificación clínica en los trastornos mentales graves: trastorno bipolar, depresión y esquizofrenia. Rev Psiquiatr Salud Ment (Barc.). 2019;12:106–115.

* Corresponding author.

E-mail address: albert@uniovi.es (M.P. Garcia-Portilla).

PALABRAS CLAVE

Estadificación;
Psiquiatría;
Trastorno bipolar;
Depresión;
Esquizofrenia

Estadificación clínica en los trastornos mentales graves: trastorno bipolar, depresión y esquizofrenia

Resumen La estadificación clínica es una herramienta diagnóstica utilizada en otras especialidades de la medicina que surge de la combinación de un enfoque categorial y dimensional. En las últimas 2 décadas, se ha planteado su aplicación en el campo de la psiquiatría, fundamentalmente como herramienta de ayuda diagnóstica, de orientación terapéutica y pronóstica. En este trabajo se revisan los modelos de estadificación clínica que han sido propuestos hasta la fecha para el trastorno bipolar, la depresión y la esquizofrenia. Se realizó una búsqueda bibliográfica en las bases de datos PubMed y Medline. Se seleccionaron con base en los criterios de inclusión y exclusión un total de 15 estudios. Se describen y comparan las características de cada uno de los modelos agrupados según el tipo de trastorno para el que fueron propuestos (trastorno bipolar: 4; depresión: 5; esquizofrenia: 6). Como conclusión, identificamos la necesidad de validar empíricamente dichos modelos para así demostrar que son una herramienta útil en la práctica clínica habitual.

© 2018 SEP y SEPB. Publicado por Elsevier España, S.L.U. Todos los derechos reservados.

Introduction**What is clinical staging?**

From the psychiatric and psychological point of view, a categorical focus has dominated in the way to understand and handle mental health problems.¹ This perspective assumes that individuals with the same diagnosis are relatively similar and present the same symptoms regardless of the individual's stage of evolution. However, conceptualising mental illness as diverse specific entities is incomplete, given that factors involving great therapeutic and prognostic differences (such as, for example, the number of comorbid diseases, the varying psychopathological profiles or the degree of deterioration in the level of functioning) are not always taken into consideration.²⁻⁶ This difficulty can be remedied from a dimensional focus, because it makes it possible to classify subjects throughout a *continuum* of severity, establishing different levels depending on the signs and symptoms of the disorder, and on the variations produced over time.

Clinical staging models arise from the combination of both approaches. In the first place, the models recognise the attributes that best characterise the subjects, classifying them in terms of all or nothing. In second place, the models quantitatively differentiate such attributes based on different levels of severity. The goal of clinical staging is to divide the course of the illness into recognisable stages that reflect the course of the illness and that are relevant for treatment and prognosis. Using a series of objective, quantifiable markers, the stage of the patient's illness is identified; this in turn makes it possible to: (1) establish the scope of the disorder, (2) emit a prognosis and (3) adopt the most appropriate therapeutic strategy. The final goal is to prevent development to more advanced stages and promote a return to less severe phases or even to complete remission.⁷ What is more, this tool represents an advancement over conventional diagnostic practice, as it not only defines the extent of the disorder at a specific time, it also

reveals its location on the *continuum* of the course of the illness.⁷

In short, applying clinical staging might help to achieve precise psychiatry, in which the goals and least harmful and most effective therapeutic actions are adjusted to each person individually.⁸

Clinical staging in psychiatry

The idea of clinical staging in mental health is not a new concept. Kraepelin, in spite of not using the term itself, was the first to indicate that the course of mental illness seemed to be progressive. Years later, in 1993, Fava and Kellner⁹ introduced the concept of clinical staging in the psychiatric environment and, since then, a wide range of proposals have appeared (see [Tables 1-3](#)).

One of the features that a disorder has to have to benefit from a clinical model of stage involves possessing a predictable clinical course over time.¹⁰ The initial stages are more benign and tend to respond to simpler therapies. In contrast, the more advanced stages require therapeutic tools of greater risk; that is, with a greater capacity to produce long-term adverse effects or physical alterations, as well as needing palliative strategies focused on the consequences and disabilities produced by the illness.¹¹ Various authors^{1,12,13} have supported the hypothesis that the natural course of severe mental illness develops from an asymptomatic state (at risk) towards non-specific symptom manifestations, such as mild anxiety and subthreshold and somatic symptoms, which can finally lead to a specific mental disorder. Likewise, numerous studies have shown that the patterns of response to treatment vary depending on the developmental stage in which the therapy is carried out.^{4,5,12,14}

The models formulated up to now are interesting. However, they are exclusively theoretical proposals. From now on, efforts should be aimed at their empirical validation. In addition, these models approach the reality of mental illness

Table 1 Most significant clinical staging models in bipolar disorder.

Author and year	Number of stages	Description of stages	Stage markers
Berk et al., 2007 ^{11,29}	7 stages: – 3 preclinical – 4 clinical	Stage 0: increased risk Stage 1a: mild, non-specific symptoms Stage 1b: prodromal symptoms Stage 2: first mood episode Stage 3a: recurrence with subsyndromal symptoms Stage 3b: recurrence with well defined symptoms Stage 4: treatment-resistant disease	Affective psychopathology
Kapczinski et al., 2009 ²⁷	5 stages: – 1 preclinical – 4 clinical	Latent stage: increased risk (genetic load) Stage 1: episodes with periods of well-defined euthymia Stage 2: residual interepisode symptoms (comorbidity and rapid cycles) Stage 3: pronounced functional and cognitive deterioration (with certain functional independence) Stage 4: total functional disability	Affective psychopathology Cognitive performance Level of functioning Biological markers (↑TNF- α , ↑3-nitrotyrosine, ↓BDNF, ↑glutathione reductase and transferase) Late stages: ↓IL 6, ↓BDNF, ↑TNF- α
^a Kauer-Sant'Anna et al., 2009 ³³			Stages III and IV: worse functioning (FAST)
^a Rosa et al., 2014 ³²			Late stages: ↑IL 6
^a Grande et al., 2014 ³¹			Late stages: more complex treatments
^a De Goi et al., 2015 ⁵³			Stages III and IV: ↑sTNFR-80, ↓sIL-2R
^a Siwek et al., 2017 ³⁴			Late stages: ↑MMP-9, ↑sICAM-1
^a Reininghaus et al., 2016 ³⁶			Late stages: neuroanatomical changes
^a Mwangi et al., 2016 ¹⁸			Late stages: smaller hippocampal volume and worse performance in verbal learning
^a Cao et al., 2016 ¹⁹			Early stages: ↑IL-10
^a Tatay-Manteiga et al., 2017 ³⁵			
Cosci and Fava, 2013 ⁷	5 stages: – 2 preclinical – 3 clinical	Stage 1a: mild, non-specific symptoms (prodromal phase) Stage 1b: cyclothymia Stage 2: first mood episode Stage 3: residual interepisode symptoms with pronounced functional and cognitive deterioration Stage 4: frequent mood episodes in spite of drug treatment	Psychopathology Cognitive performance Level of functioning
Duffy, 2014 ³⁰	6 stages: – 1 preclinical – 4 clinical	Stage 0: genetic load and mood disorders Stage 1: episodes of anxiety and problems with sleeping Stage 2: depressive episodes, dysthymia, cyclothymia or adaptative disorders Stage 3: recurrent depressive episodes Stage 4a: hypomanic or manic episode (with or without psychotic symptoms) Stage 4b: pronounced impact of the illness on health (addictions, physical comorbidities)	Family psychiatric history Personal psychiatric history Psychopathology

^a Partial validations of Kapczinski's²⁷ model.

Table 2 Most significant clinical staging models in unipolar depression.

Author and year	Number of stages	Description of stages	Stage markers
Fava and Kellner, 1993 ⁹	6 stages: – 1 preclinical – 5 clinical	Stage 1: prodromal phase (anxiety, irritability, anhedonia and sleep problems) Stage 2: first major depressive episode (DEM-III-R) Stage 3: residual phase Stage 4a: dysthymia (DEM-III-R) Stage 4b: recurrent depressive episodes Stage 5: chronic depressive disorder (lasting more than 2 years)	Affective psychopathology (significant number of prior episodes)
Fava and Tossani, 2007 ³⁸	11 stages: – 3 preclinical – 8 clinical	Stage 1: prodromal phase – 1a: no depressive symptoms (anxiety, irritability, anhedonia and sleep problems) accompanied by mild functional deterioration – 1b: having depressive symptoms Stage 2: first major depressive episode Stage 3: residual phase – 3a: no depressive symptoms (sleep problems, anxiety, irritability, anorexia and sexual dysfunction) – 3b: with affective symptoms (depressive mood, feelings of blame and desperation) – 3c: dysthymia Stage 4a: recurrent depressive episodes Stage 4b: double depression Stage 5: major depressive disorder	Affective psychopathology (significant number of prior episodes) Affective psychopathology (significant number of prior episodes) Level of functioning
Cosci and Fava, 2013 ⁷			
Hetrick et al., 2008 ³⁷	8 stages: – 3 preclinical – 5 clinical	Stage 0: increased risk of anxiety or depression (genetic load) Stage 1a: mild or non-specific symptoms of anxiety and depression with mild changes in functional and cognitive performance Stage 1b: subclinical symptoms of anxiety and depression with moderate deficits in functional and cognitive performance (GAF < 70) Stage 2: first major depressive episode with moderate to severe deterioration in functional and cognitive performance (GAF: 30–50) Stage 3a: partial remission of the episode Stage 3b: new depressive episode Stage 3c: multiple recurrences Stage 4: severe, resistant disease (symptoms that do not remit, deterioration in functional and cognitive performance)	Affective psychopathology (significant number of prior episodes) Cognitive performance Level of functioning
^a Verduijn et al., 2015 ³⁹			Affective psychopathology (importance of time of exposure to depressive state) Cognitive performance Level of functioning

GAF: Global Assessment of Functioning.

^a Validation of the Hetrick et al. (2008) model.

Table 3 Most significant clinical staging models in schizophrenia.

Author and year	Number of stages	Description of stages	Stage markers
Fava and Kellner, 1993 ⁹	5 stages: – 1 preclinical – 4 clinical	Stage 1: prodromal phase (affective and negative symptomatology) with deterioration in functioning. Stage 2: acute episode Stage 3: residual phase Stage 4: subchronic phase (from 6 to 24 months) Stage 5: chronic phase (>24 months)	Psychopathology
Lieberman et al., 2001 ⁴⁴	4 stages: – 2 preclinical – 2 clinical	Stage 1: premorbid phase (mild physical changes, poor motor coordination, limited cognitive performance and social deficits) Stage 2: prodromal phase (non-specific affective symptoms, sleep problems, deterioration in attention and memory, mild psychotic symptoms psicóticos and changes in behaviour) Stage 3: commencement of the illness; deteriorating phase (psychotic symptoms, cognitive deterioration, negative symptomatology and social deficits) Stage 4: chronic phase/residual phase (limited efficacy of the antipsychotics)	Psychopathology Cognitive performance Social abilities Underlying physiopathological processes
Singh et al., 2005 ⁴⁵	5 stages: – 2 preclinical – 3 clinical	Stage 1: prodromal phase (P) (affective, behavioural, thought processing, perception and non-specific functioning changes) P1: non-diagnostic symptoms minimally present P2: presence of non-diagnostic symptoms Stage 2: first psychotic symptoms Stage 3: diagnostic impression of schizophrenia Stage 4: definitive diagnosis of schizophrenia	Psychopathology Cognitive performance Level of functioning Social abilities
McGorry et al., 2010 ⁴²	8 stages: – 3 preclinical – 5 clinical	Stage 0: increased risk of psychotic or mood disorders, without the presence of symptoms Stage 1a: mild, non-specific symptoms with slight changes in functional and cognitive performance Stage 1b: moderate symptoms with striking changes in functional and cognitive performance (GAF < 70) Stage 2: severe psychotic or affective symptoms with pronounced functional and cognitive deterioration (GAF 30–50) Stage 3a: partial remission of the first episode Stage 3b: new episode Stage 3c: multiple relapses Stage 4: severe and resistant disease (symptoms that do not remit, deterioration in functional and cognitive performance)	Psychopathology Cognitive performance Level of functioning Electrophysiological markers (eye movements, P50, prepulse inhibition, etc.) Neurobiological markers (HPA dysregulation, oxidative stress markers) Neuroanatomical markers
Agius et al., 2010 ⁴⁹	3 stages: – 1 preclinical – 2 clinical	Stage 1: prodromal phase Stage 2: first psychotic episode Stage 3: definitive diagnosis of schizophrenia	Psychopathology Cognitive performance Neuroanatomical changes
Cosci and Fava, 2013 ⁷	4 stages: – 1 preclinical – 3 clinical	Stage 1: prodromal phase with deterioration in functioning Stage 2: acute manifestations Stage 3: residual phase Stage 4: chronic phase (in attenuated or persistent form)	Psychopathology Level of functioning

GAF: Global Assessment of Functioning; HPA: hypothalamus-pituitary-adrenal axis.

only partially, given that they do not contemplate all the variables that can be relevant over the course of the illness; examples are the patient's physical health,^{15,16} health-related quality of life¹⁷ or neuroanatomical markers.^{18,19}

Method

We present a selective review of clinical staging in severe mental illness, specifically in bipolar disorder (BD), depression and schizophrenia. A general search of the PubMed databases was performed with the following search strategy: ((staging[Other Term]) AND (schizophrenia[Mesh Terms] OR bipolar disorder[Mesh Terms] OR depression[Mesh Terms])). In order to find other relevant references, the bibliography of the articles selected was performed. Next, we screened the results to select studies based on the following inclusion criteria: (1) studies whose study objective was the proposal of a clinical staging model for BD, depression or schizophrenia, (2) ones that clearly described the different stages proposed, and (3) those written in English or Spanish.

Results

From the electronic search, a total of 35 articles were obtained and from the manual search, a total of 20. Applying the inclusion criteria, only 15 articles precisely described a staging model for each of the disorders studied; the others either did not describe a model or referred to previous models.

Clinical staging in bipolar disorder

Over the last two decades, experts have considered that the etiopathogenesis of BD involves the presence of an active neurodevelopmental process that, at least partially, is mediated by inflammatory processes, oxidative stress, apoptosis and alterations in neurogenesis.^{20–22} These features make it an ideal disorder to benefit from a clinical staging model.²⁰

Likewise, clinical evidence supports its development from prodromal (preclinical) stages towards more severe, treatment-resistant stages.²³ An example of this would be the decrease in euthymia time, the increase in frequency and severity of episodes, the greater risk of recurrence and the increase in sensitivity to stress factors over time.²⁴ Patients who have experienced 10 or more episodes more frequently present inability to work, worse level of functioning and poor quality of life, in addition to more severe, more persistent symptoms. The concept of allostatic load, which refers to the physiological mechanisms of adaptation to stress, would make it possible to integrate these findings.^{25–27} In addition, studies examining response to treatment reveal that both the psychological treatments and the pharmacological treatments are more effective if they are implemented in the initial stages.^{14,28}

In the last few years, different theoretical clinical staging models for BD have been proposed (see [Table 1](#)). The first one, developed by Berk et al.,²⁹ consists of 7 stages centred around variables of psychopathology in affective disorders. It begins with an asymptomatic period, in which factors of risk are mainly identified (Stage 0, of increased risk),

after which the patient can either advance towards Stage 1a (presence of mild, non-specific symptoms) or directly towards Stage 1b (manifestation of prodromal symptoms). After that, the first affective episode may present (Stage 2, the first episode of mood disorder). Stage 3 (recurrence) is classified based on the number and type of episodes: Stage 3a (recurrence with symptoms of sub-syndromal mood disorders); Stage 3b (recurrence with well defined symptoms) and Stage 3c (multiple recurrences). Finally, in Stage 4 (treatment-resistant disease), the authors describe a patients whose clinical development is characterised by symptoms that are persistent and resistant to treatment. Years later, these authors proposed the most appropriate therapeutic strategies for each of the different stages.¹¹

In 2009, Kapczinski et al.,²⁷ posed a second, 5-stage, model that incorporated cognitive, functional and biological marker variables besides including affective psychopathology. It established a different prognosis and treatment for each stage. The model has 4 stages: a preclinical one (Stage 0, latent) and 3 clinical ones. Stage 1 is characterised by the presence of mood episodes separated by clear periods of euthymia. Next, in Stage 2, these euthymic periods become contaminated by residual symptoms. In Stage 3, there is a pronounced cognitive and functional deterioration, whose worsening leads to Stage 4; that is, to the presence of complete functional incapacity. Years later, in 2013, Cosci and Fava⁷ developed a 4-stage model similar to that of their predecessors, but eliminating the preclinical stage because they considered that the prodromal manifestations were highly non-specific and did not make it possible to discriminate among the different types of disorders. In contrast, Duffy et al.,³⁰ keeping in mind BD's elevated heritability, again included a preclinical stage defined solely by the presence of confirmed family BD history; they considered the descendants of these patients to be a high-risk group. Their model, in addition to incorporating this preclinical stage, distinguished between 2 subgroups of patients: those that progressed to a classic BD and the ones that developed a bipolar spectrum disorder (patients with mixed or psychotic symptoms). Their model is made up of 6 stages and establishes different clinical markers depending on the subgroup to which the patient belongs.³⁰

Without arriving at the proposal of a specific model, several authors have identified potentially useful variables to classify patients with BD according to severity, such as level of functioning^{31,32} and biological markers.^{31,33–36} Specifically, alterations have been observed in several inflammatory parameters in the late stages (III–IV) of BD: interleukins 1 (sIL-2R),³⁴ 6 (IL-6)^{31,33} and 10 (IL-10)³⁵; soluble tumour necrosis factor receptor 80 (sTNFR-80)³⁴; brain-derived neurotrophic factor (BDNF)³³; matrix metalloproteinase MMP-9³⁶ and soluble intercellular adhesion molecule 1 (sICAM-1)³⁶ (see [Table 1](#) for further information).

Likewise, Mwngi et al.,¹⁸ found neuroanatomical differences between patients in early, intermediate and late stages. Patients in more advanced stages presented greater brain structure alterations, which gives support to the hypothesis of neurodevelopment in BD and the usefulness of staging models. In a neuroimaging study, Cao et al.,¹⁹ found that late-stage patients had a smaller hippocampal volume and greater difficulties in verbal learning than control subjects. These studies indicate that neuroanatomical

alterations seem to be potential markers for clinical staging of BD.

Clinical staging in depression

Clinical staging models have been developed for major depression with 2 different aims: classify the progression of the illness and resistance to treatment. In this review, we will focus on the first (see Table 2), given that the second are limited to resistant depressions.

With these models, it is understood that applying a staging model in depression could make it possible to delay or prevent disease onset, as well as increase the number of individuals treated appropriately, reduce the severity of the disorder or prevent its development.^{6,37}

Fava and Kellner⁹ developed the first clinical staging model for unipolar depression, which was later updated in 2007.³⁸ This model has 6 stages and is based on affective symptomatology and the number of episodes. According to these authors, depression begins with a prodromal phase characterised by the presence of risk factors without depressive symptoms (Stage 1a) or by subdepressive symptoms that do not reach the severity of an episode (Stage 1b). From that point on, individuals can present the first depressive episode (Stage 2). Next comes the residual phase (Stage 3), which may consist of an asymptomatic period (Stage 3a) or of a stage in which the diagnostic criteria for dysthymic disorder are fulfilled (Stage 3b). Stage 4 is characterised by the presence of multiple recurrences (Stage 4a) and, if dysthymia has been present, the diagnosis of double depression is proposed (Stage 4b). Lastly, Stage 5 is reached when there are no remission periods and the depressive episode lasts more than 2 years. In 2013, a new version⁷ was put forward, in which the level of functioning was added as a variable that determined the step between stages. The residual phase was also divided into 3 stages: (1) non-affective symptoms such as sleep problems, anxiety or sexual dysfunction, (2) dysthymia and (3) depressive symptoms.

In 2008, Hetrick et al.,³⁷ proposed an adaptation of the McGorry¹² model for psychotic and mood disorders. This model consists of 8 stages and takes into consideration changes in the patient's cognitive performance and level of functioning. The first 3 are preclinical stages, while the characteristic symptoms of a major depressive disorder develop over the next 5 (Stage 2: first depressive episode; Stage 3a: partial remission of the first depressive episode; Stage 3b: recurrence; Stage 3c: multiple recurrences and Stage 4: severe and persistent major depressive disorder determined by the severity of the psychopathology and its strong repercussion on cognition and functioning). Verduijn et al.,³⁹ examined the predictive validity of the staging model proposed by Hetrick.³⁷ Their investigation showed that using a staging model based on purely clinical stages is reasonable for major depressive disorder. However, and in contrast to what was thought, the time of exposure to the depressive state seemed to characterise the clinical stages better than the number of previous depressive episodes.

As for physiological parameters, no investigations identifying biomarkers capable of distinguishing between disease progression stages were found.⁴⁰ For that matter, the psychopathological mechanisms involved in the aetiology of

depression have not been found to be linked to its clinical progression.⁴¹

Clinical staging in schizophrenia

Schizophrenia is a complex mental disorder with long evolution, whose symptoms generally emerge during adolescence and early adulthood. Our current classification systems lack diagnostic validity, especially in the first phases, when symptoms are still appearing and have not become sufficiently developed to fit the existing syndromic criteria. This is mainly due to the difficulty in distinguishing between the transitory or normative changes stemming from neurodevelopment, and changes that precede the development of a mental disorder.⁴² Creating staging models that allow the incorporation of prodromal stages together with therapeutic strategies adapted would make it possible to reduce the degree of deterioration associated with the disorder. Such models would also prevent progression to more advanced stages.

The bases for applying clinical staging models in schizophrenia started from the agreement between the neuroanatomical brain studies (grey matter changes) described by Pantelis et al.,⁴³ and the clinical-based studies by McGorry et al.¹² The first theoretical staging model for schizophrenia was proposed by Fava and Kellner⁹ (see Table 3). This model has 5 stages based solely on psychopathology. The stages are as follows: Stage 1, prodromal symptoms (mainly affective and negative) with limitations of functioning; Stage 2, acute episode; Stage 3, residual symptoms; Stage 4, subchronic symptoms (lasting from 6 to 24 months); and Stage 5, chronic symptoms (lasting longer than years). In 2001, Lieberman et al.⁴⁴ proposed a new 4-stage model that included biological markers and indications of cognitive and social functioning, in addition to psychopathological variables. In 2005, Singh et al.⁴⁵ proposed 5 stages in the development of schizophrenia: prodromal phases (P1: non-diagnostic symptoms minimally present; P2: presence of diagnostic symptoms), first psychotic symptoms, diagnostic impression of schizophrenia and chronic stage (definitive diagnosis). Earlier, Cannon et al.⁴⁶ had described a premonitory stage, occurring before the prodromal phases, in which signs of neurodevelopmental delay could be seen, seeming to indicate an increase in the risk of developing schizophrenia in the future. Years later, McGorry et al.⁴ developed an 8-stage model whose main innovation was including electrophysiological, neurobiological and neuroimaging markers. After many modifications,^{47,48} the final model consisted of the following stages: Stage 0, increased risk of psychotic disorder without the presence of symptoms; Stage 1a, presence of non-specific or mild symptoms; Stage 1b, moderate subsyndromal symptoms; Stage 2, onset of the first psychotic episode; Stage 3a, partial remission of the first episode; Stage 3b, recurrence or relapse of the psychotic disorder; Stage 3c, multiple recurrences of greater clinical severity and impact of the disease; and Stage 4, severe and persistent disease. In 2010, Agius et al.⁴⁹ proposed a 3-stage model based on the cognitive, neuroanatomical and clinical impact of the disease. Finally, Cosci and Fava⁷ posited a model that integrated the previous proposals, consisting of 4 stages: (1) prodromal symptoms with deterioration of functioning;

(2) acute manifestations; (3) residual phase; and (4) chronic phase (either attenuated or persistent).

Over the last few years, there have been several studies demonstrating the usefulness of a focus based on clinical staging for schizophrenia. To begin with, in 2016 a study showed that the variations in cell adherence (particularly the sICAM-1 molecule) reflected a biochemical staging model in schizophrenia.⁵⁰ In addition, Dragioti et al.⁵¹ examined the differences in 3 groups of patients with a diagnosis of schizophrenia (classified according to age) on the Positive and Negative Syndrome Scale for schizophrenia. The study results indicated that the course of schizophrenia seemed to reflect a process ranging from coherent mental functioning with consciousness of disease, through disorganisation to, finally, neurocognitive deterioration. Another recent study⁵² has shown that individuals with a single episode of schizophrenia present less severe scores on the positive, disorganised and hostility factor dimensions than those who have undergone more than one episode. These findings provide empiric support (partial validations) to the idea of staging in schizophrenia. However, further studies that determine specific clinical and biological markers for each stage are needed, as well as others that take the multidimensional nature of the disorder into consideration.

Discussion

Over the last 2 decades, the staging models in severe mental illness (specifically, in BD, depression and schizophrenia) have been evolving and progressing due to the clinical need to stage the patients in order to bring us closer to precision medicine.

This article presents the results of a selective review of the staging models for severe mental illness proposed up until now. It is necessary to point out that, in spite of the models available, none of them have had their validity shown empirically.

In relation to BD, there were 4 models developed towards the end of the first decade in the 21st century: the model proposed by Kapczinski et al.²⁷ is the one that has evolved and progressed the most. For example, Rosa et al.³² classified 54 patients according to Kapczinski's model. They used a semi-structured interview and chose as the bases the course of the illness, the presence of comorbid illnesses and the level of functioning (work, social relationships and self-care). Study results showed evidence in favour of clinical staging in BD, given that the patients in initial stages demonstrated better functioning than those in later stages. Following the same methodology, De Goi et al.⁵³ showed that patients in early stages required simpler pharmacological strategies than those classified in more advanced stages. Lastly, there is another study in which low levels of sIL-2R and high levels of sTNFR-80 in serum are characteristic of late stages.³⁴ In spite of the fact that it might seem that these studies validate the model proposed by Kapczinski, they only do so partially: some are based on functioning, others on treatment and yet others on some specific biomarkers. The rest of the studies found were limited to identifying variables that discriminated between early and late stages, without even proposing any specific staging model.^{18,19,31,33,36}

With respect to unipolar depression, 3 staging models have been proposed. All of them clearly define a prodromal phase, but there are differences as to the number of preclinical stages that make it up. The only model validated empirically is that developed by Hetrick et al.³⁷ Their research demonstrated the predictive validity of clinical staging models for depression. In addition, these authors found that how long the episodes lasted had greater predictive power than the number of previous episodes.

As for clinical staging models for schizophrenia, we have found 6 theoretical proposals. The last one, from Cosci and Fava,⁷ integrated all the previous proposals and set out 4 stages: prodromal, acute manifestations, residual and chronic phase. The rest of the studies on patients with this diagnosis are based on dividing the sample according to years of evolution and finding markers that distinguish between early and late stages; however, they do not validate the staging models proposed to date.

Future studies must carry out longitudinal research and establish the predictive value of the clinical staging models for the different disorders mentioned. The goals should include improving diagnostic capability and making it more precise: from the initial stages of the illness, with the need for early detection, to the more advanced stages, with the need to identify resulting complications and deficits (psychiatric and somatic comorbidities, and losses in the level of functioning and in quality of life). An additional objective should be to encourage the application of interventions adapted to patient needs according to the stage in which the individuals are found.

Conclusions

From what has been indicated, we can conclude that the clinical staging models traditionally used by other medical specialities might also be applicable to mental and behavioural illnesses. Specifically, various theoretical staging models have been established for BD, depression and schizophrenia in the last decade. However, empirical validity has been shown for only one of those developed for depression. For these reasons, and in spite of all the effort carried out to date, it remains essential to validate the models developed up until now or to create new empirical staging models whose validity has been demonstrated for routine clinical practice.

Funding

Lorena de la Fuente-Tomás has a contract under the Severo Ochoa Predoctoral Aid Programme for research and teaching in the Principado de Asturias.

This study was funded by the Ministry of Economy and Competitiveness, the Carlos III Healthcare Institute (PI14/02037 and PI16/01761) and the European Regional Development Fund (ERDF).

Conflict of interests

The authors have no conflicts of interest to declare.

References

- Hickie IB, Scott J, Hermens DF, Scott EM, Naismith SL, Guastella AJ, et al. Clinical classification in mental health at the crossroads: which direction next? *BMC Med.* 2013;11:125.
- Fava GA, Rafanelli C, Tomba E. The clinical process in psychiatry: a clinimetric approach. *J Clin Psychiat.* 2012;73:177–84.
- Hickie IB. Commentary on 'Evaluating treatments for the mood disorders: Time for the evidence to get real'. *Aust N Z J Psychiatry.* 2004;38:415–8.
- McGorry PD, Purcell R, Hickie IB, Yung AR, Pantelis C, Jackson HJ. Clinical staging: a heuristic model for psychiatry and youth mental health. *Med J Aust.* 2007;187:40–2.
- Scott J. Bipolar disorder: from early identification to personalized treatment. *Early intervention in psychiatry.* *J Clin Psychiat.* 2011;5:89–90.
- Guidi J, Tomba E, Cosci F, Park SK, Fava GA. The role of staging in planning psychotherapeutic interventions in depression. *J Clin Psychiat.* 2017;78:456–63.
- Cosci F, Fava GA. Staging of mental disorders: systematic review. *Psychother Psychosom.* 2013;82:20–34.
- Salagre E, Grande I, Sole B, Sanchez-Moreno J, Vieta E. Vortioxetine: a new alternative for the treatment of major depressive disorder. *Rev Psiquiatr Salud.* 2018;11:48–59.
- Fava GA, Kellner R. Staging: a neglected dimension in psychiatric classification. *Acta Psychiat Scand.* 1993;87:225–30.
- Berk M, Berk L, Dodd S, Cotton S, Macneil C, Daglas R, et al. Stage managing bipolar disorder. *Bipolar Disord.* 2014;16:471–7.
- Berk M, Conus P, Lucas N, Hallam K, Malhi GS, Dodd S, et al. Setting the stage: from prodrome to treatment resistance in bipolar disorder. *Bipolar Disord.* 2007;9:671–8.
- McGorry PD, Hickie IB, Yung AR, Pantelis C, Jackson HJ. Clinical staging of psychiatric disorders: a heuristic framework for choosing earlier, safer and more effective interventions. *Aust N Z J Psychiatry.* 2006;40:616–22.
- Lin A, Reniers RL, Wood SJ. Clinical staging in severe mental disorder: evidence from neurocognition and neuroimaging. *Br J Psychiatry.* 2013;54:11–7.
- Berk M, Brnabic A, Dodd S, Kelin K, Tohen M, Malhi GS, et al. Does stage of illness impact treatment response in bipolar disorder? Empirical treatment data and their implication for the staging model and early intervention. *Bipolar Disord.* 2011;13:87–98.
- Garcia-Portilla MP, Saiz PA, Bascaran MT, Martinez AS, Benabarre A, Sierra P, et al. Cardiovascular risk in patients with bipolar disorder. *J Affect Disorders.* 2009;115:302–8.
- Garcia-Portilla MP, Saiz PA, Benabarre A, Sierra P, Perez J, Rodriguez A, et al. The prevalence of metabolic syndrome in patients with bipolar disorder. *J Affect Disorders.* 2008;106:197–201.
- Anaya C, Torrent C, Caballero FF, Vieta E, Mar Bonnin C, Ayuso-Mateos JL. Cognitive reserve in bipolar disorder: relation to cognition, psychosocial functioning and quality of life. *Acta Psychiat Scand.* 2016;133:386–98.
- Mwangi B, Wu MJ, Cao B, Passos IC, Lavagnino L, Keser Z, et al. Individualized prediction and clinical staging of bipolar disorders using neuroanatomical biomarkers. *Biol Psychiatry Cogn Neurosci Neuroimaging.* 2016;1:186–94.
- Cao B, Passos IC, Mwangi B, Bauer IE, Zunta-Soares GB, Kapczinski F, et al. Hippocampal volume and verbal memory performance in late-stage bipolar disorder. *J Psychiatr Res.* 2016;73:102–7.
- Scott J, Leboyer M, Hickie I, Berk M, Kapczinski F, Frank E, et al. Clinical staging in psychiatry: a cross-cutting model of diagnosis with heuristic and practical value. *Br J Psychiatry.* 2013;202:243–5.
- Roda A, Chendo I, Kunz M. Biomarkers and staging of bipolar disorder: a systematic review. *Trends Psychiatry Psychother.* 2015;37:3–11.
- Leboyer M, Soreca I, Scott J, Frye M, Henry C, Tamouza R, et al. Can bipolar disorder be viewed as a multi-system inflammatory disease? *J Affect Disorders.* 2012;141:1–10.
- Vieta E, Reinares M, Rosa AR. Staging bipolar disorder. *Neurotox Res.* 2011;19:279–85.
- Reinares M, Papachristou E, Harvey P, Mar Bonnin C, Sanchez-Moreno J, Torrent C, et al. Towards a clinical staging for bipolar disorder: defining patient subtypes based on functional outcome. *J Affect Disorders.* 2013;144:65–71.
- Grande I, Magalhaes PV, Kunz M, Vieta E, Kapczinski F. Mediators of allostasis and systemic toxicity in bipolar disorder. *Physiol Behav.* 2012;106:46–50.
- Vieta E, Popovic D, Rosa AR, Sole B, Grande I, Frey BN, et al. The clinical implications of cognitive impairment and allostatic load in bipolar disorder. *Eur Psychiatry.* 2013;28:21–9.
- Kapczinski F, Dias VV, Kauer-Sant'Anna M, Frey BN, Grassi-Oliveira R, Colom F, et al. Clinical implications of a staging model for bipolar disorders. *Expert Rev Neurother.* 2009;9:957–66.
- Joyce K, Thompson A, Marwaha S. Is treatment for bipolar disorder more effective earlier in illness course? A comprehensive literature review. *Int J Bipolar Disord.* 2016;4:19.
- Berk M, Hallam KT, McGorry PD. The potential utility of a staging model as a course specifier: a bipolar disorder perspective. *J Affect Disorders.* 2007;100:279–81.
- Duffy A. Toward a comprehensive clinical staging model for bipolar disorder: integrating the evidence. *Can J Psychiatry.* 2014;59:659–66.
- Grande I, Magalhaes PV, Chendo I, Stertz L, Panizutti B, Colpo GD, et al. Staging bipolar disorder: clinical, biochemical, and functional correlates. *Acta Psychiat Scand.* 2014;129:437–44.
- Rosa AR, Magalhaes PV, Czepielewski L, Sulzbach MV, Goi PD, Vieta E, et al. Clinical staging in bipolar disorder: focus on cognition and functioning. *J Clin Psychiat.* 2014;75:450–6.
- Kauer-Sant'Anna M, Kapczinski F, Andreazza AC, Bond DJ, Lam RW, Young LT, et al. Brain-derived neurotrophic factor and inflammatory markers in patients with early- vs. late-stage bipolar disorder. *Int J Neuropsychopharmacol.* 2009;12:447–58.
- Siwek M, Sowa-Kucma M, Styczen K, Misztak P, Nowak RJ, Szewczyk B, et al. Associations of serum cytokine receptor levels with melancholia, staging of illness, depressive and manic phases, and severity of depression in bipolar disorder. *Mol Neurobiol.* 2017;54:5883–93.
- Tatay-Manteiga A, Balanza-Martinez V, Bristot G, Tabares-Seisdedos R, Kapczinski F, Cauli O. Clinical staging and serum cytokines in bipolar patients during euthymia. *Prog Neuropsychopharmacol Biol Psychiatry.* 2017;77:194–201.
- Reininghaus EZ, Lackner N, Birner A, Bengesser S, Fellen-dorf FT, Platzer M, et al. Extracellular matrix proteins matrix metalloproteinase 9 (MMP9) and soluble intercellular adhesion molecule 1 (sICAM-1) and correlations with clinical staging in euthymic bipolar disorder. *Bipolar Disord.* 2016;18:155–63.
- Hetrick SE, Parker AG, Hickie IB, Purcell R, Yung AR, McGorry PD. Early identification and intervention in depressive disorders: towards a clinical staging model. *Psychother Psychosom.* 2008;77:263–70.
- Fava GA, Tossani E. Prodromal stage of major depression. *Early Interv Psychiatry.* 2007;1:9–18.
- Verduijn J, Milaneschi Y, van Hemert AM, Schoevers RA, Hickie IB, Penninx BW, et al. Clinical staging of major depressive disorder: an empirical exploration. *J Clin Psychiat.* 2015;76:1200–8.
- Meana JJ, Mollinedo-Gajate I. Biomarkers in Psychiatry: between myth and clinical reality. *Rev Psiquiatr Salud.* 2017;10:183–4.

41. Verduijn J, Milaneschi Y, Schoevers RA, van Hemert AM, Beekman AT, Penninx BW. Pathophysiology of major depressive disorder: mechanisms involved in etiology are not associated with clinical progression. *Transl Psychiat*. 2015;5:649.
42. McGorry PD, Nelson B, Goldstone S, Yung AR. Clinical staging: a heuristic and practical strategy for new research and better health and social outcomes for psychotic and related mood disorders. *Can J Psychiatry*. 2010;55:486–97.
43. Pantelis C, Velakoulis D, McGorry PD, Wood SJ, Suckling J, Phillips LJ, et al. Neuroanatomical abnormalities before and after onset of psychosis: a cross-sectional and longitudinal MRI comparison. *Lancet*. 2003;361:281–8.
44. Lieberman JA, Perkins D, Belger A, Chakos M, Jarskog F, Boteva K, et al. The early stages of schizophrenia: speculations on pathogenesis, pathophysiology, and therapeutic approaches. *Biol Psychiatry*. 2001;50:884–97.
45. Singh SP, Cooper JE, Fisher HL, Tarrant CJ, Lloyd T, Banjo J, et al. Determining the chronology and components of psychosis onset: the Nottingham Onset Schedule (NOS). *Schizophr Res*. 2005;80:117–30.
46. Cannon TD, van Erp TG, Bearden CE, Loewy R, Thompson P, Toga AW, et al. Early and late neurodevelopmental influences in the prodrome to schizophrenia: contributions of genes, environment, and their interactions. *Schizophr Bull*. 2003;29:653–69.
47. Yung AR, McGorry PD. Prediction of psychosis: setting the stage. *Br J Psychiatry Suppl*. 2007;51:1–8.
48. McGorry PD. Issues for DSM-V: clinical staging: a heuristic pathway to valid nosology and safer, more effective treatment in psychiatry. *Am J Psychiatry*. 2007;164:859–60.
49. Agius M, Goh C, Ulhaq S, McGorry P. The staging model in schizophrenia, and its clinical implications. *Psychiatr Danub*. 2010;22:211–20.
50. Stefanovic MP, Petronijevic N, Dunjic-Kostic B, Velimirovic M, Nikolic T, Jurisic V, et al. Role of sICAM-1 and sVCAM-1 as biomarkers in early and late stages of schizophrenia. *J Psychiatr Res*. 2016;73:45–52.
51. Dragioti E, Wiklund T, Siamouli M, Moutou K, Fountoulakis KN. Could PANSS be a useful tool in the determining of the stages of schizophrenia? A clinically operational approach. *J Psychiatr Res*. 2017;86:66–72.
52. Ortiz BB, Eden FD, de Souza AS, Teciano CA, de Lima DM, Noto C, et al. New evidence in support of staging approaches in schizophrenia: differences in clinical profiles between first episode, early stage, and late stage. *Compr Psychiatry*. 2017;73:93–6.
53. Goi PD, Bucker J, Vianna-Sulzbach M, Rosa AR, Grande I, Chendo I, et al. Pharmacological treatment and staging in bipolar disorder: evidence from clinical practice. *Rev Bras Psiquiatr*. 2015;37:121–5.